65th ASH Annual Meeting & Exposition: 652. Multiple Myeloma: Clinical and Epidemiological: Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma

Symposia: Multiple Myeloma: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Biological therapies, adult, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Lymphoid Malignancies, Study Population, Human

Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)

Moderators:

Joselle Cook, MBBS, Mayo Clinic and Moshe E Gatt, MD, Probook C//O Ceva Logistics (EGL)

Disclosures:

No relevant conflicts of interest to declare.

This session includes studies on bispecific antibodies and CAR T cells for the treatment of relapsed/refractory multiple myeloma. Major focus of the abstratcs is the prediction of side effects and response to these novel immunotherapies. Target audience is the physician with a strong interest in multiple myeloma and access to bispecific antiboides as well as CAR T cells within and outside clinical trials.

4:30 PM

1003

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial

Michel Delforge¹^*, Krina K. Patel, MD, MSc², Laurie Eliason, MPH³^*, Devender Dhanda, PhD³^*, Ling Shi, PhD⁴^*, Shien Guo, PhD⁴^*, Thomas S. Marshall, PharmD³^*, Bertrand Arnulf, MD, PhD⁵, Michele Cavo, MD⁶^*, Ajay K. Nooka, MD, MPH⁷, Salomon Manier, MD, PhD⁸, Natalie S. Callander, MD⁹, Sergio A. Giralt, MD, FACP¹⁰, Hermann Einsele, MD, PhD¹¹^*, Sikander Ailawadhi¹², Mihaela Popa-McKiver, PhD³^*, Mark Cook, MBChB, PhD¹³ and Paula Rodríguez Otero, MD¹⁴^*

¹University Hospital Leuven, Leuven, Belgium
²The University of Texas MD Anderson Cancer Center, Houston, TX
³Bristol Myers Squibb, Princeton, NJ
⁴Evidera, Bethesda, MD
⁵Hôpital Saint-Louis, APHP, Université Paris cite, Paris, France
⁶Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
⁷Winship Cancer Institute, Emory University, Atlanta, GA
⁸Centre Hospitalier Universitaire de Lille, Lille, France
⁹University of Wisconsin Carbone Cancer Center, Madison, WI
¹⁰Memorial Sloan Kettering Cancer Center, New York, NY
¹¹Medizinische Klinik und Poliklinik II, Uniklinikum Würzburg, Würzburg, Germany
¹²Mayo Clinic, Jacksonville, FL
¹³Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
¹⁴Clínica Universidad de Navarra, Pamplona, Spain

4:45 PM

1004

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Doris K. Hansen, MD¹^*, Lauren C. Peres, PhD, MPH¹^*, Julieta Abraham Miranda, PhD¹^*, Kayla Reid, MS¹^*, Gabriel De Avila, MS¹^*, David Huggar, PharmD, MS²^*, Pallavi Patwardhan, PhD, BSPharm²^*, Laura B. Oswald, PhD³^*, Ariel F. Grajales-Cruz, MD⁴, Brandon Blue, MD⁵, Hien Liu, MD¹, Taiga Nishihori, MD⁶, Kenneth Shain, MD, PhD⁴^*, Rachid Baz, MD⁴, Melissa Alsina, MD¹^*, Omar Castaneda, MD⁷, Simran K. Tiwana²^*, Afraim Botros, PharmD, RPh²^*, Frederick L. Locke, MD¹ and Ciara Louise L. Freeman, MD, PhD, MSc¹

¹H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
²Bristol Myers Squibb, Princeton, NJ
³Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL
⁴H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
⁵Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁶Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
⁷Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

5:00 PM

1005

Cumulative Incidence and Characteristics of Infections Requiring Treatment, Delay in Treatment Administration or Hospitalisation in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti BCMA or Anti GPRC5D Bispecific Antibodies

Elise Cellerin¹^*, Aurelie Jourdes²^*, Xavier Brousse³^*, Nicolas Vallet⁴^*, Tom Cartau⁵^*, Blandine Denis, MD⁶^*, Stephanie Harel, MD⁷^*, Simon Jamard⁸^*, Alexis Redor⁹^*, Titouan Cazaubiel¹⁰^*, Virginie Roland¹¹^*, Carine Caleteix¹²^*, Morgane Charles¹²^*, Pierre Berger¹³^*, Guillaume Escure¹⁴^*, Aude Collignon¹³^*, Emmanuel Faure¹⁵^*, Clarisse Cazelles¹⁶^*, Fanny Lanternier¹⁷^*, Clementine de La Porte Des Vaux¹⁸^*, Laurent Frenzel, MD, PhD¹⁹^*, Mathieu Blot²⁰^*, Francois Danion²¹^*, Cécile Sonntag, MD²²^*, Cyrille Touzeau, MD, PhD²³^*, Andrea Pieragostini²⁴^*, Florence Ader²⁵^*, Lionel Karlin²⁶^*, Margaret Macro, MD²⁷^*, Guillaume martin-Blondel, PHD²⁸^*, Thomas Chalopin, MD²⁹^* and Aurore Perrot, MD, PhD³⁰

¹Centre hospitalier universitaire de Tours, Hospital, Tours, France
²Centre hospitalier universitaire de Toulouse, Hospital, Toulouse, France
³Infectiology, CHU de Bordeaux, Bordeaux, France
⁴Centre Hospitalier Universitaire de Tours/Service d'hématologie et thérapie cellulaire, Université de Tours, Tours, France
⁵Centre hospitalo-universitaire de Caen, Caen, France
⁶Infectious diseases, Saint Louis Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
⁷Saint Louis Hospital, Paris, France
⁸Centre Hospitalier Universitaire de Tours/Service d'infectiologie et maladie tropicale, Centre Hospitalier Université de Tours, Tours, France
⁹Centre hospitalier de Perpignan, Centre hospitalier de Perpignan, Perpignan, France
¹⁰CHU De Bordeaux, Bordeaux, FRA
¹¹CH DE PERPIGNAN, Perpignan, FRA
¹²Centre hospitalier de Perpignan, Perpignan, France
¹³Centre hospitalier et universitaire de Marseille, Marseille, France
¹⁴Centre Hospitalo-universitaire de Lille, Lille, French Guiana
¹⁵centre hospitalo-universitaire de Lille, Lille, FRA
¹⁶Hopital Necker, Paris, FRA
¹⁷Assistance Publique-hôPitaux De Paris (AP-HP), HôPital Necker Enfa, Paris, FRA
¹⁸Hopital Necker, paris, France
¹⁹Department of Haematology, Institut Necker, Paris, FRA
²⁰Centre hospitalo-universitaire de Dijon, Dijon, France
²¹Centre hospitalo-universitaire de Strasbourg, Strasbourg, France
²²Centre Hospitalier Universitaire Hautepierre, Strasbourg, FRA
²³Centre Hospitalier Universitaire de Nantes, Nantes, France
²⁴Hematology, CHU Dijon, Dijon, France
²⁵Centre hospitalo-universitaire de Lyon, Lyon, France
²⁶Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France
²⁷Hopital Cote De Nacre, Caen, France
²⁸Centre hospitalier universitaire de Toulouse, Centre hospital-universitaire de Toulouse, Toulouse, France
²⁹Centre hospitalier universitaire de Tours, Hospital, Tours, FRA
³⁰Service Hematologie, CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France

5:15 PM

1006

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Darren Pan, MD¹, Tarek H. Mouhieddine, MD², Weijia Fu³^*, Erin Moshier⁴^*, Samir Parekh, MD², Sundar Jagannath, MD², Adriana C Rossi, MD, MSc², Joshua Richter, MD¹, Cesar Rodriguez, MD²^*, Larysa J Sanchez, MD², Santiago Thibaud, MD²^*, Hearn Jay Cho, MD⁵ and Shambavi Richard, MD²

¹Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
²Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
³Icahn School of Medicine at Mount Sinai, New York, NY
⁴Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, NY
⁵Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Tisch Cancer Institute, New York, NY

5:30 PM

1007

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Sridevi Rajeeve, MD¹, Nicole Zahradka, PhD²^*, Matt Wilkes, MD, PhD²^*, Darren Pan, MD³, Nicholas J Calafat, MS⁴^*, Kseniya Serebryakova⁵^*, Katerina Kappes, BSc³^*, Hayley Jackson⁶^*, Nicole Buchenholz, MS⁵^*, Sarita Agte, MD⁷^*, Santiago Thibaud, MD³^*, Larysa Sanchez, MD³^*, Shambavi Richard, MD⁸, Joshua Richter, MD³, Cesar Rodriguez, MD⁸^*, Hearn Jay Cho, MD⁹, Ajai Chari, MD¹⁰, Sundar Jagannath, MD^8,11, Adriana C Rossi, MD, MSc⁸ and Samir Parekh, MD⁸

¹Myeloma & Cellular Therapy Services, Memorial Sloan Kettering Cancer Center, New York, NY
²Current Health, Inc., Boston, MA
³Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
⁴Current Health Inc, Boston, MA
⁵Icahn School of Medicine at Mount Sinai, New York, NY
⁶Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY
⁷Dorset County Hospital, NHS Foundation Trust, Dorchester, United Kingdom
⁸Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
⁹Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Tisch Cancer Institute, New York, NY
¹⁰University of California at San Francisco, San Francisco, CA
¹¹Mount Sinai Medical Center, New York, NY

5:45 PM

1008

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

Luise Fischer¹^*, Patrick Born¹^*, Ronald Weiss^2,3^*, Nora Grieb¹^*, Sabine Seiffert²^*, Andreas Boldt²^*, Stephan Fricke³^*, Paul Franz³^*, Christina Kloetzer¹^*, Simone Heyn¹^*, Ronny Baber^4,5^*, Song-Yau Wang¹^*, Enrica Bach¹^*, Sandra Hoffmann¹^*, Jule Ussmann¹^*, Janine Kirchberg¹^*, Klaus H Metzeler, MD⁶, Marco Herling¹^*, Madlen Jentzsch¹^*, Georg-Nikolaus Franke¹^*, Ulrich Sack²^*, Kristin Reiche³^*, Ulrike Koehl^2,3^*, Uwe Platzbecker, MD⁷, Vladan Vucinic, M.D.¹^* and Maximilian Merz, MD¹

¹Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany
²Institute of Clinical Immunology, University Hospital of Leipzig, Leipzig, Germany
³Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany
⁴Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig Medical Center, Leipzig, Germany
⁵Leipzig Medical Biobank, University Leipzig, Leipzig, Germany
⁶Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University Leipzig Medical Center, Leipzig, NA, Germany
⁷Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University Medical Center Leipzig, Leipzig, Germany

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

652.O1.6 652. Multiple Myeloma: Clinical and Epidemiological: Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma